umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine. (Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan)
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine.
Show others and affiliations
2009 (English)In: Liver transplantation, ISSN 1527-6465, E-ISSN 1527-6473, Vol. 15, no 10, 1229-1235 p.Article in journal (Refereed) Published
Abstract [en]

Liver transplantation (LTx) for familial amyloidotic polyneuropathy (FAP) is an accepted treatment for this fatal disease. However, the long-term outcome with respect to that of nontransplanted patients has not been fully elucidated. The aim of this study was to compare the long-term survival of Swedish LTx FAP patients with that of historical controls, especially with respect to the age at onset of the disease and gender. In order to evaluate the outcome of LTx as a treatment for FAP, survival was calculated from the onset of disease. One hundred forty-one FAP patients, 108 transplanted and 33 not transplanted, were included in the study. Significantly increased survival was noted for LTx patients in comparison with controls. The outcome was especially favorable for those with an early onset of the disease (age at onset < 50 years) in comparison with early-onset controls (P < 0.001). In contrast, no significant difference for late-onset cases (> or = 50 years) was found. Transplanted late-onset females had significantly improved survival in comparison with transplanted late-onset males (P = 0.02). We were unable to find significant differences in survival between patients with long (> or = 7 years) or short (<7 years) disease duration at transplantation. The survival of male patients with late-onset disease appeared not to improve with LTx. LTx is an efficacious treatment for improving the survival of early-onset FAP patients. Further studies are needed to analyze the cause of the poorer outcome for late-onset male patients.

Place, publisher, year, edition, pages
John Wiley & Sons, 2009. Vol. 15, no 10, 1229-1235 p.
National Category
Public Health, Global Health, Social Medicine and Epidemiology
Research subject
Medicine
Identifiers
URN: urn:nbn:se:umu:diva-31345DOI: 10.1002/lt.21817PubMedID: 19790145OAI: oai:DiVA.org:umu-31345DiVA: diva2:292590
Available from: 2010-02-08 Created: 2010-02-08 Last updated: 2012-08-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Okamoto, SadahisaWixner, JonasSuhr, Ole B

Search in DiVA

By author/editor
Okamoto, SadahisaWixner, JonasSuhr, Ole B
By organisation
Medicine
In the same journal
Liver transplantation
Public Health, Global Health, Social Medicine and Epidemiology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 64 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf